[
    [
        {
            "time": "2023-10-01",
            "original_text": "It's important that the government invests in vaccines: Dr. Dan Barouch",
            "features": {
                "keywords": [
                    "government",
                    "invests",
                    "vaccines",
                    "Dr. Dan Barouch"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 2,
                "Duration": 9,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Novartis immuno-oncology drug candidate fails skin cancer trial",
            "features": {
                "keywords": [
                    "Novartis",
                    "immuno-oncology",
                    "drug",
                    "fails",
                    "skin cancer",
                    "trial"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar速 + Mekinist速 in advanced melanoma",
            "features": {
                "keywords": [
                    "Novartis",
                    "Phase III",
                    "spartalizumab",
                    "PDR001",
                    "Tafinlar速",
                    "Mekinist速",
                    "advanced melanoma"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]